Frank E Uschner
Overview
Explore the profile of Frank E Uschner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
652
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Juanola A, Ma A, de Wit K, Gananandan K, Roux O, Zaccherini G, et al.
Gut
. 2023 Oct;
73(1):156-165.
PMID: 37884354
Background: Patients with decompensated cirrhosis experience high mortality rates. Current prognostic scores, including the model for end-stage liver disease (MELD), may underperform in settings other than in those they were...
2.
Gu W, Schaaf L, Hortlik H, Zeleke Y, Brol M, Schnitzbauer A, et al.
Eur J Gastroenterol Hepatol
. 2023 Sep;
35(11):1289-1297.
PMID: 37724476
Background: To date, liver transplantation (LT) is the only curative treatment for cirrhosis and early-diagnosed progressive acute liver failure (ALF). However, LT results in morbidities and mortality even post-LT. Different...
3.
Gu W, Zeleke Y, Hortlik H, Schaaf L, Uschner F, Schulz M, et al.
Hepatol Commun
. 2023 Sep;
7(10).
PMID: 37708430
Background: The number of complications in patients admitted for cirrhosis has increased over time. Portal hypertension is the driver of many complications of cirrhosis. TIPS placement is the most effective...
4.
Ortiz C, Klein S, Reul W, Magdaleno F, Groschl S, Dietrich P, et al.
Cell Rep
. 2023 Feb;
42(2):112059.
PMID: 36729833
Development of liver fibrosis is paralleled by contraction of hepatic stellate cells (HSCs), the main profibrotic hepatic cells. Yet, little is known about the interplay of neprilysin (NEP) and its...
5.
Queck A, Schwierz L, Gu W, Ferstl P, Jansen C, Uschner F, et al.
Hepatology
. 2022 Jul;
77(2):466-475.
PMID: 35869810
Background: Ascites is a definitive sign of decompensated liver cirrhosis driven by portal hypertension. Although transjugular intrahepatic portosystemic shunt insertion (TIPS) is indicated for therapy of recurrent and refractory ascites,...
6.
Schulz M, Mengers J, Gu W, Drolz A, Ferstl P, Amoros A, et al.
Liver Int
. 2022 Jun;
43(1):180-193.
PMID: 35727853
Background & Aims: In ACLF patients, an adequate risk stratification is essential, especially for liver transplant allocation, since ACLF is associated with high short-term mortality. The CLIF-C ACLF score is...
7.
Niu L, Geyer P, Gupta R, Santos A, Meier F, Doll S, et al.
Mol Syst Biol
. 2022 May;
18(5):e10947.
PMID: 35579278
Deeper understanding of liver pathophysiology would benefit from a comprehensive quantitative proteome resource at cell type resolution to predict outcome and design therapy. Here, we quantify more than 150,000 sequence-unique...
8.
Artzner T, Conti S, Cortesi P, Sacleux S, Fernandez J, Morelli M, et al.
Liver Transpl
. 2022 May;
28(9):1429-1440.
PMID: 35544360
There is growing evidence that liver transplantation (LT) is the most effective treatment for acute-on-chronic liver failure grade-3 (ACLF-3). This study examines whether and how this evidence translates into practice...
9.
Gu W, Hortlik H, Erasmus H, Schaaf L, Zeleke Y, Uschner F, et al.
Lancet Reg Health Eur
. 2021 Dec;
12:100240.
PMID: 34901909
Background: Cirrhosis is known to have a high prevalence and mortality worldwide. However, in Europe, the epidemiology of cirrhosis is possibly undergoing demographic changes, and etiologies may have changed due...
10.
Torres S, Brol M, Magdaleno F, Schierwagen R, Uschner F, Klein S, et al.
Front Mol Biosci
. 2021 Sep;
8:715765.
PMID: 34513923
Activation of the inflammasome NLRP3 (NOD-, LRR- and pyrin domain containing 3) contributes to the development of non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH). Therefore, this...